ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Poonam Bansal1, Varruchi Sharma2, Anil Panwar3, Raman Kumar4, Aanchal Sharma5, Seema Ramniwas5, Abhijit Dey6, Deepak Chandran7, Kuldeep Dhama8 and Anil K Sharma1
1Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana Ambala, Haryana, India.
2Department of Biotechnology & Bioinformatics, Sri Guru Gobind Singh College Sector 26, Chandigarh, India.
3Department of Bioinformatics and Computational Biology, College of Biotechnology, CCS Haryana Agricultural University, Hisar, Haryana, India.
4Department of Biochemistry, Kurukshetra University, Kurukshetra, Haryana, India.
5University Centre for Research and Development, University Institute of Biotechnology Chandigarh University, Gharuan, Mohali, India.
6Department of Life Sciences, Presidency University, 86/1 College Street, Kolkata, West Bengal, India.
7Department of Veterinary Sciences and Animal Husbandry, Amrita School of Agricultural Sciences, Amrita Vishwa Vidyapeetham University, Coimbatore, Tamil Nadu, India.
8Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh, India.
Article Number: 8395 | © The Author(s). 2023
J Pure Appl Microbiol. 2023;17(1):385-394.
Received: 30 December 2022 | Accepted: 19 January 2023 | Published online: 01 March 2023
Issue online: March 2023

SARS-CoV-2 is continually evolving with the emergence of new variants with increased viral pathogenicity. The emergence of heavily mutated Omicron (B.1.1.529) with spike protein mutations are known to mediate its higher transmissibility and immune escape that has brought newer challenges for global public health to contain SARS-CoV-2 infection. One has to come up with a therapeutic strategy against the virus so as to effectively contain the infection and spread. Natural phytochemicals are being considered a significant source of bioactive compounds possessing an antiviral therapeutic potential. Being a promising anticancer and chemo-preventive agent, Silybin holds a significant potential to be used as a therapeutic. In the present study, molecular docking of Silybin with Omicron spike protein (7QNW) was carried out. Molecular docking results showed greater stability of Silybin in the active site of the Omicron spike protein with suitable binding mode of interactions. The study reveals that Silybin has the potential to block the host ACE2 receptor-viral spike protein binding; thereby inhibiting the viral entry to human cells. Therefore, Silybin may be further developed as a medication with the ability to effectively combat SARS-CoV-2 Omicron.


SARS CoV-2 Omicron, Spike Protein, Phytochemicals, Computational Approach, Antiviral Drugs

Article Metrics

Article View: 723

Share This Article

© The Author(s) 2023. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.